U
lcerative Colitis (UC) and Crohn's disease (CD) are idiopathic inflammatory conditions of the bowel that can involve organs other than the gastrointestinal tract. The reported frequency of extraintestinal manifestations ranges from 6% in a single population-based study 1 to 47% in case control studies. 2, 3 Vascular complications, mostly thromboembolic events (TE), have been described, 1, 4, 5 and IBD patients have a 3-fold risk of deep vein thrombosis and pulmonary embolism as compared with the general population. 4, 6 The reported frequency of TE in IBD varies widely in the literature 4, 5 from 0.3% in clinical studies to 41% in autoptic studies. The annual incidence rate of venous thromboembolism in both UC and CD was approximately 0.5% in a population-based cohort of IBD patients from Manitoba. 6 Arterial TE have also been reported 7, 8 and, more recently, CD has been associated to a higher rate of cerebral arterial TE whereas an increased risk of cardiac arterial TE was evidentiated in all IBD patients. 9 TE are more frequent in young IBD patients and carry a significant risk of mortality. 10 Many IBD patients with TE have active disease or a recent history of major abdominal surgery. By converse, a large study found that 77% of peripheral venous thromboses occurred whereas the disease was in clinical remission. 4 It has hence been suggested that IBD may be associated with a thrombotic tendency independent from disease activity. Corticosteroids, often used chronically in these patients because of steroid dependency, can also induce a hypercoagulable state and subsequently increase the thrombotic risk. 11 Finally, several autoptic studies had showed in CD patients microthrombi located in blood vessels of the intestinal mucosa, 12 suggesting that vascular involvement could be the first pathogenetic step in the development of mucosal damage.
Risk factors for thrombosis are classified as acquired and genetic. Acquired risk factors, all frequent in IBD patients, include inflammation, prolonged immobilization or hospitalization, surgery, steroid therapy, fluid depletion, smoking, oral contraceptives, central venous catheters, and hyperhomocysteinemia. The most common genetic prothrombotic factors are Factor V Leiden (FVL), prothrombin G20210A mutations, and homozygous C677T mutation in the methylenetetrahydrofolate reductase (MTHFR). 13 Over the last years, discrepant results were reported on their role in TE in IBD patients. 10, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Most studies found no significant difference in the rate of the above mentioned mutations between IBD patients who developed TE and subjects without IBD who experienced TE, but at least 2 reports suggest an increased frequency of mutated alleles for thrombophilia in IBD. 21, 31 Two more recent studies 32, 33 identified an increased expression of other candidate genes for TE, offering new clues for further research. The aim of our study has been to investigate an extended panel of genetic factors associated with prothrombotic condition in a homogeneous cohort of Mediterranean IBD patients with and without TE compared with a healthy control population. Fasting peripheral venous blood samples were collected in vacutainer tubes that contained EDTA for mutation analysis and for other blood tests (Hb, WBC, PLT, ESR, CRP, total cholesterol, HDL-cholesterol, fibrinogen). They were stored at -201C until determination. The following 14 gene polymorphisms were evaluated using Cardio and Thrombo Test (Nuclear Laser Medicine srl, Settala, Milano, Italy): 2 polymorphisms of Factor V (Factor V R506Q and Factor V H1299R), 1 polymorphism of Factor II (prothrombin G20210A), 2 polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677 T and MTHFR A1298C), 1 polymorphism of cystathionine b synthase (CBS T833C/844ins68), 1 polymorphism of plasminogen activator inhibitor (PAI-1 4G/4G), 1 polymorphism of cholesterol ester transfer protein (CEPT I405 V), 1 polymorphism of platelet glycoprotein IIIa (GPIIIa T1565C), 1 polymorphism of cholesterol 7a-hydroxylase (CYP7A1 A278C), 1 polymorphism of angiotensin-converting enzyme (ACE D/D), 2 polymorphisms of genes encoding for apolipoproteins (ApoE T112C and T158C), and 1 polymorphism for angiotensinogen (AGT M235 T).
The test is based on the reverse hybridization principle and includes 3 steps: (1) DNA is extracted from anticoagulated blood by a rapid procedure using 6100 PREP STATION (Applied Biosystems, Monza, Milano, Italy), a nucleic acids automatic purification system; (2) relevant gene sequences are simultaneously amplified by ''real time'' PCR and biotin-labelled; (3) amplification products are hybridized to a test strip which contains allele-specific (wild-type and mutant) oligonucleotide probes as an array of parallel lines. Bound biotinylated sequences are detected using streptavidin-alkaline phosphatase and color substrates.
Statistical analysis has been carried out using the software Statistical Analysis System (SAS, Cary, NC). Continuous variables are expressed as mean±standard deviation, categorical variables as rate or percentage. Chisquare test and Fisher exact test when necessary have been used to compare genotypic distribution and allelic frequency. A difference was considered statistically significant when P<0.05.
RESULTS
Twenty-six women and 14 men were investigated; mean age was 47.1 (SD±17.24) years. Twenty-one had CD and nineteen had UC. Patients' baseline features are given in Table 1 . Nine IBD patients (22.5%) had a history of TE (Table 2) . These patients had a mean age of 57.5 (SD±14) years. Rates of genetic polymorphisms and mutations are reported in Table 3 . No significant difference in allelic frequency was found between IBD patients and controls except AGT T/T, though a trend toward significance was found also for ACE D/D. No significant difference was observed between CD and UC patients. Eight out of 9 patients with earlier history of TE had more than 1 polymorphism (Table 4) , while in patients without TE this is less frequent (12/31) and no more than 2 polymorphisms were observed. Smoking habits and contraceptive consumption in IBD patients were not associated with TE.
For the analysis of mutations of the ACE gene, genotypes I/D and I/I were pooled and compared with genotype D/D, whereas for the AGT gene genotypes M/M and M/T were pooled and compared with genotype T/T. In patients with IBD the mutation AGT T/T was related with male sex (P<0.0259) and, marginally, with arterial hypertension (P<0.06) and diabetes (P<0.09). 
DISCUSSION
Research on the role of genetic prothrombotic factors in IBD has led to conflicting results. 10, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Most studies found no significant difference in the rate of mutations between IBD patients who developed TE and patients without IBD who experienced TE, but at least 2 reports suggest an increased frequency of mutated alleles for thrombophilia in IBD. 21, 31 In the study by Liebman et al, 21 FVL mutation was found in 36% of 11 IBD patients with history of TE versus 4% of 51 IBD patients without history of TE. Similar results were reached by Oldenburg et al. 31 In the last 2 years, two more studies have addressed this topic looking for expression of a larger panel of polymorphisms. In particular, Koutroubakis et al 32 identified an increased expression of the alleles FV R506Q and PAI-1 4G/4G in IBD while Yilmaz et al 33 reported an increased allelic frequency of X-Fibrinogen 455 G-A, MTHFR A1298C and ACE I/D. These results suggest the involvement of factors others than those commonly associated with TE in subjects without IBD. The reason for conflicting results could be due to the different characteristics of patients enrolled in previous studies in terms of genetic background, ethnic origin, sample size, and number of TE. Discrepant results could be explained also by the different mixing in various series of genetic and acquired conditions predisposing to TE. Studies in the Mediterranean area investigating the expression of the most common genes associated with TE, that is FVL, MTHFR mutations, and Factor II G20210A, did not find associations with IBD. 20, 25, 26, 30 However, as suggested by other studies, in IBD other candidate genes could act as triggers for TE. 32, 33 Although the number of patients is small and the number of TE events modest, our study accounts for a consecutive, ethnically homogenous series of Sicilian patients investigated using an extensive panel of 14 genes associated with vascular events which, to our knowledge, has never been assessed in this setting. In agreement with a majority of studies, we were unable to show a different frequency of the most common genetic prothrombotic factors (again FVL, MTHFR mutations and Factor II G20210A) in patients with IBD with or without TE as compared to controls. Nonetheless, we have demonstrated the expression of multiple polymorphisms and mutations in IBD patients with TE, a potentially relevant finding that suggests that multiple genes may contribute to the development and increased risk of TE. We also found an increased frequency of AGT T/T, which has never been reported so far in IBD, and, even if not statistically significant, of the genotypes ACE D/D, confirming the results of Yilmaz et al. These genes are more commonly (20) associated with arterial TE. ACE plays a role in platelet activation and aggregation, while the AGT gene is linked to early atherosclerosis, essential hypertension and atrial fibrillation. 34, 35 Indeed, early atherosclerosis is a clinical feature common to several inflammatory and immunological diseases and a well-recognized marker of accelerated atherogenesis, that is the intima-media thickness (IMT) of the common carotid artery, has recently been detected in patients with inflammatory bowel disease. 36 Genetic polymorphisms of AGT and ACE predisposing to atherogenesis could be crucial in determining mesenteric microvascular thrombosis that many investigators believe to be a contributing factor in the pathogenesis of IBD. In CD a pathological angiogenesis could also play a critical role in perpetuating and amplifying the inflammatory process. These findings are in keeping with a recent epidemiology study 37 that found an increased rate of arterial vascular complications in IBD.
Genetic profiling and identification of acquired factors could both help in stratifying patients at risk to choose the best candidates for heparin prophylaxis thus minimizing side effects. Even if results of clinical trials, in which anticoagulant drugs were used as the first treatment for IBD, have shown that they are safe, 38 fear of hemorrhagic complications is still a matter of concern among gastroenterologists worldwide. At the present time heparin is recommended in hospitalized patients with IBD in general by the American Society of Thromboembolism, 39 while the British Society of Gastroenterology 40 recommends pharmacological prophylaxis for TE only in hospitalized patients with severe UC.
We suggest the use of genetic profiling for TE to improve the selection of patients at risk in view also of the potential clinical implications of the recent large retrospective study by Grainge et al 41 which reports an even higher risk of TE during flares of IBD in nonhospitalized patients, thus extending the indications to heparin prophylaxis.
In conclusion, our study focused on a comprehensive evaluation of genetic factors related to thrombophilia in a group of IBD patients with or without history of TE, and found a possible role of two genes, ACE and AGT, which needs, in consideration of the small sample size, to be confirmed in larger series and in multicentric studies.
